|
|
Post by Clement on Jul 24, 2024 6:09:04 GMT -5
|
|
|
|
Post by porkini on Jul 24, 2024 6:20:36 GMT -5
And you don't even have to wait to listen to the call if you're an early bird...  "SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 31, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location." |
|
|
|
Post by Clement on Jul 31, 2024 6:27:13 GMT -5
Bet on q2 results? This is mine: 71m$ rev Royalties 25,2 Collab%serv 26 Afrezza 16 Vgo 3,8 Earnings: 0,04 Actual T-DPI revs reported this morning by UTHR === $258.3M. This translates to $25.8M in T-DPI royalties for Mannkind. It looks like parrerob's bet is going to be close. If so, Mannkind's Q2 revs will show a significant beat over the average analyst estimate, which is currently $64.8M on Yahoo Finance. ---------And let's not leave out casualinvestor's "optimistic Q2" in his post which estimates royalties at of $26M. mnkd.proboards.com/post/266837/thread . |
|
|
|
Post by neil36 on Jul 31, 2024 7:20:17 GMT -5
Keep in mind that MNKD sold 1% of the royalty stream for cash (ten percent of MNKD's share), so of the $25.8, they would only keep $23.22 million
|
|
|
|
Post by prcgorman2 on Jul 31, 2024 8:12:14 GMT -5
Keep in mind that MNKD sold 1% of the royalty stream for cash (ten percent of MNKD's share), so of the $25.8, they would only keep $23.22 million From an accounting perspective my guess is MNKD reports 10% royalties as revenue, and 10% of the 10% (1%) as an expense paid to Sagard Healthcare. The result is as you've described. |
|
|
|
Post by celo on Jul 31, 2024 9:29:09 GMT -5
Tyvaso DPI Cost of sales for UTHR was 33 million last quarter and 37.6 million this quarter. With royalty going from 22.5 to 25.8. Trying to find where collar/services would show up in United's quarterly report.
|
|
|
|
Post by neil36 on Jul 31, 2024 10:10:35 GMT -5
That's a 14% increase in costs for UTHR. Last quarter MNKD recognized $24.8 million in collaboration revenue. A corresponding 14% increase would put my guess for this quarter at $28.27 million
|
|
|
|
Post by celo on Jul 31, 2024 10:34:00 GMT -5
collaboration and services:
1q23. 11.4 million
2q23 11.2 million
3q13 13 million
4q13 17.2 million
1q14 24.8 million
You can see a big jump from 4q23 to 1q24. Will that number be similar? If history is any indication the answer is yes.
It may come in even higher as United had a big quarter of DPI sales which will have drained down inventories that would need to be replenished.
|
|
|
|
Post by prcgorman2 on Jul 31, 2024 10:53:36 GMT -5
I expect Afrezza revenues to be inline with the estimate parrerob offered ($16M) but it might be slightly higher because of the INHALE-3 symposium at ADA. INHALE-1 (pediatrics), INHALE-3 (pump/switch) and Cipla in India are wildcards for Afrezza. I expect modest improvement in sales until the pediatrics results. The slide deck accompanying the 1Q earnings indicated label changes with both the INHALE-3 and INHALE-1 trial results. If the pediatrics trial results are especially good, next year may finally be time for sayhey24 's full-court press dramatic change in marketing to include dropping the price, bribing the PBMs for Tier 1 placement, lobbying hard for the SoC change, liberal free samples, and DTC advertising. |
|
|
|
Post by celo on Jul 31, 2024 10:55:14 GMT -5
So Q2
Royalty. 25.8
Collab/serv 24.2
Afrezza 17
v-go 3
Total: 70
I believe Afrezza could surprise upward by another 1-2 million
|
|
|
|
Post by prcgorman2 on Jul 31, 2024 10:57:16 GMT -5
Yup. I think collaboration and services is the big question mark. Will it be similar to 1Q or revert to 4Q 2023 levels?
|
|
|
|
Post by celo on Jul 31, 2024 11:37:51 GMT -5
|
|
|
|
Post by Clement on Jul 31, 2024 13:48:15 GMT -5
Tyvaso DPI Cost of sales for UTHR was 33 million last quarter and 37.6 million this quarter. With royalty going from 22.5 to 25.8. Trying to find where collar/services would show up in United's quarterly report. Mannkind's "collaboration and services" category includes what UTHR pays for manufacturing. It also includes collaboration fees, recognition of deferred revenue, etc. UTHR's "cost of sales" is defined in the UTHR 10Q (page 27) as "Cost of Sales Our cost of sales primarily includes costs to manufacture our products, royalty and sales-based milestone payments under license agreements granting us rights to sell related products, direct and indirect distribution costs incurred in the sale of our products, and the costs of inventory reserves for current and projected obsolescence. These costs also include share-based compensation and salary-related expenses for direct manufacturing and indirect support personnel, quality review and release for commercial distribution, direct materials and supplies, depreciation, facilities-related expenses, and other overhead costs." |
|
|
|
Post by Clement on Aug 7, 2024 7:23:10 GMT -5
Bet on q2 results? This is mine: 71m$ rev Royalties 25,2 Collab%serv 26 Afrezza 16 Vgo 3,8 Earnings: 0,04 Here's my bet for Q2 2024 revenues: Royalties 27 Coll & Svcs 25 Afrezza 16 VGo 4 Total $72M This is less than 10% increase over Q1 2024. Not bad. |
|
|
|
Post by mpg54 on Aug 7, 2024 11:55:11 GMT -5
We’re now at a 288m a year run rate. I think that’s so impressive considering not long ago 100m seemed a daunting task. I still think Afrezza has huge untapped potential after listening to the Juicebox podcast with Dr Blevins. I think It’s becoming less of an unknown or failed drug and more of a why aren’t you trying it. Yet, reality is 64m a year, 10 years in…
|
|
